8225

China Health GroupSEHK:8225 Stock Report

Market Cap

HK$492.7m

7D

7.6%

1Y

3.1%

Updated

16 Sep, 2021

Data

Company Financials
8225 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance5/6
Financial Health6/6
Dividends0/6

8225 Overview

China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China.

Price History & Performance

Summary of all time highs, changes and price drops for China Health Group
Historical stock prices
Current Share PriceHK$0.49
52 Week HighHK$0.33
52 Week LowHK$0.70
Beta-3.61
1 Month Change30.26%
3 Month Change17.86%
1 Year Change3.13%
3 Year Change163.30%
5 Year Change132.39%
Change since IPO20.73%

Recent News & Updates

Apr 14
Should You Be Adding China Health Group (HKG:8225) To Your Watchlist Today?

Should You Be Adding China Health Group (HKG:8225) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

8225HK Life SciencesHK Market
7D7.6%-2.9%-2.4%
1Y3.1%90.1%7.3%

Return vs Industry: 8225 underperformed the Hong Kong Life Sciences industry which returned 90.1% over the past year.

Return vs Market: 8225 underperformed the Hong Kong Market which returned 7.3% over the past year.

Price Volatility

Is 8225's price volatile compared to industry and market?
8225 volatility
8225 Beta-3.61
Industry Beta1.1
Market Beta1

Stable Share Price: 8225 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 8225's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199885n/ahttps://www.chgi.net

China Health Group Inc., an investment holding company, provides clinical research services to pharmaceutical and biotechnology companies in the People’s Republic of China. The company offers contracted clinical research services; contracted pharmaceutical development services; post launch market research, medical, and medical market services; medical science liaisons; and other medical services. It also provides hospital management, medical tourism, and specialized hospital services, as well as Venturepharma cloud; and sells drugs technologies.

China Health Group Fundamentals Summary

How do China Health Group's earnings and revenue compare to its market cap?
8225 fundamental statistics
Market CapCN¥407.24m
Earnings (TTM)CN¥61.79m
Revenue (TTM)CN¥89.13m

6.6x

P/E Ratio

4.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
8225 income statement (TTM)
RevenueCN¥89.13m
Cost of RevenueCN¥16.70m
Gross ProfitCN¥72.43m
ExpensesCN¥10.64m
EarningsCN¥61.79m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.062
Gross Margin81.26%
Net Profit Margin69.32%
Debt/Equity Ratio0.0%

How did 8225 perform over the long term?

See historical performance and comparison

Valuation

Is China Health Group undervalued compared to its fair value and its price relative to the market?

6.59x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 8225 (HK$0.5) is trading above our estimate of fair value (HK$0.46)

Significantly Below Fair Value: 8225 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 8225 is good value based on its PE Ratio (6.6x) compared to the Hong Kong Life Sciences industry average (50.6x).

PE vs Market: 8225 is good value based on its PE Ratio (6.6x) compared to the Hong Kong market (10.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8225's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8225 is good value based on its PB Ratio (2.9x) compared to the HK Life Sciences industry average (6.6x).


Future Growth

How is China Health Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Health Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has China Health Group performed over the past 5 years?

41.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8225 has a high level of non-cash earnings.

Growing Profit Margin: 8225's current net profit margins (69.3%) are higher than last year (46.5%).


Past Earnings Growth Analysis

Earnings Trend: 8225's earnings have grown significantly by 41% per year over the past 5 years.

Accelerating Growth: 8225's earnings growth over the past year (79.9%) exceeds its 5-year average (41% per year).

Earnings vs Industry: 8225 earnings growth over the past year (79.9%) exceeded the Life Sciences industry 57.3%.


Return on Equity

High ROE: 8225's Return on Equity (43.4%) is considered outstanding.


Financial Health

How is China Health Group's financial position?


Financial Position Analysis

Short Term Liabilities: 8225's short term assets (CN¥183.6M) exceed its short term liabilities (CN¥42.8M).

Long Term Liabilities: 8225 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 8225 is debt free.

Reducing Debt: 8225 currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: 8225 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 8225 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is China Health Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 8225's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 8225's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8225's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8225's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8225's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

China Health Group has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 8225's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: 8225's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

China Health Group Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: China Health Group Inc.
  • Ticker: 8225
  • Exchange: SEHK
  • Founded: 1998
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$492.699m
  • Shares outstanding: 995.35m
  • Website: https://www.chgi.net

Number of Employees


Location

  • China Health Group Inc.
  • Building 17
  • Jianwai SOHO
  • Beijing
  • 102200
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 15:29
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.